Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of AZD4547 plus tislelizumab in FGFR-altered advanced urothelial carcinoma
CTR20222326Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib, tislelizumab in transitional cell carcinoma (TCC), sponsored by Abbisko Therapeutics. Started Oct 2022; status: active.
02
Drugs
fexagratinibtislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20222326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222326.